Dynavax Technologies


Commercial-stage biopharmaceutical company focused on development, manufacturing and commercialization of vaccines. Scientific focus centers on adjuvant technologies that target innate immune receptors (notably TLR biology) to enhance vaccine immunogenicity. Activities include clinical development, out-licensing and partnerships, biomanufacturing, regulatory submissions and publication of preclinical and clinical findings.

Industries

Pharmaceutical Manufacturing

Nr. of Employees

large (251-1000)

Dynavax Technologies

Düsseldorf, North Rhine-Westphalia, Germany


Patents

Production of vaccines comprising inactivated SARS-CoV-2 viral particles

US-12605442-B2

View Details

Shingles vaccines comprising a TLR9 agonist

US-12569553-B2

View Details

Toll-like receptor antagonist compounds and methods of use

US-12378255-B2

View Details

Immunogenicity of a CpG-adjuvanted recombinant plague vaccine

US-12364745-B2

View Details

Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

US-12296002-B2

View Details

Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof

US-11981670-B2

View Details
View All Patents

Products

HEPLISAV-B

Recombinant hepatitis B vaccine formulated with a TLR9-targeting adjuvant for prevention of hepatitis B infection in adults 18 years and older. Approved and marketed in multiple jurisdictions.

Clinical-stage herpes zoster vaccine candidate (z-1018)

Phase 1/2 randomized, observer-blinded trial evaluating safety, tolerability and immunogenicity of an investigational herpes zoster vaccine candidate formulated with a TLR9-targeting adjuvant.

rF1V plague vaccine candidate (rF1V with adjuvant)

Phase 2 randomized trial evaluating immunogenicity and safety of a recombinant plague vaccine candidate formulated with a TLR-targeting adjuvant.

CpG 1018

Dynavax’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant designed to increase antibody concentrations and stimulate strong immune responses.

Biovac-B

A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Wockhardt Ltd, India.

Gen Vax B

A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Serum Institute of India.

View All Products

Services

Providing TLR-targeting oligonucleotide adjuvant technology to selected research institutions and partners to support adjuvanted vaccine development.

Process development, GMP manufacturing support and technology transfer for recombinant antigens and vaccine candidates using established yeast expression platforms.

Expertise Areas

  • Vaccine development
  • Adjuvant development (TLR agonists)
  • Clinical trial management
  • Biomanufacturing and process development
  • Show More (5)

Key Technologies

  • Toll-like receptor (TLR) biology and TLR9-targeting synthetic oligonucleotide adjuvants
  • TLR7/8 agonist development
  • Yeast expression system (Hansenula polymorpha) for recombinant protein production
  • Recombinant antigen production
  • Show More (4)

News & Updates

Announcement regarding acquisition agreement to add a marketed adult hepatitis B vaccine and a Phase 1/2 shingles candidate to the acquirer's pipeline.

Notice of company participation at an industry healthcare conference.

Quarterly financial results release and announcement of a share repurchase program.

Curated list of peer-reviewed publications and conference presentations on TLR biology, adjuvant development and clinical trial results.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.